Hongchang International Co., Ltd

HCIL

US42831T2024

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:23:06 2024-05-31 EDT			5-day change	1st Jan Change
0.2001 ^USD	-33.30%		-.--%	-42.63%

05-15	Hongchang International Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-08	Hongchang International Co., Ltd Announces Resignation of Xingjia Gao as a Director from the Board	CI

Heyu Biological Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020

May 15, 2020 at 04:59 pm

Heyu Biological Technology Corporation announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was USD 1,395 compared to USD 21,932 a year ago. Operating loss was USD 93,878 compared to USD 48,496 a year ago. Net loss was USD 85,620 compared to USD 47,865 a year ago.

Latest news about Hongchang International Co., Ltd

Hongchang International Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Hongchang International Co., Ltd Announces Resignation of Xingjia Gao as a Director from the Board	05-08	CI
Hongchang International Co., Ltd Announces CFO Changes	05-08	CI
Hongchang International Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Hongchang International Co., Ltd Announces Board Changes	04-01	CI
Hongchang International Co., Ltd. has Changed its Ticker to HCIL from HYBT	11-28	CI
Heyu Biological Technology Corporation has Changed its Name to Hongchang International Co., Ltd	11-21	CI
Hongchang International Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Hong Chang Biotechnologies (HK) Limited completed the acquisition of Heyu Biological Technology Corporation (OTCPK:HYBT.D) in a reverse merger transaction.	23-09-03	CI
Heyu Biological Technology Corporation Appoints Zengqiang Lin as the Chief Executive Officer	23-08-23	CI
Heyu Biological Technology Corporation Announces Board and Executive Changes	23-08-23	CI
Heyu Biological Technology Corporation Appoints Wendy Wei Li as the Chief Financial Officer of the Company	23-08-23	CI
Hong Chang Biotechnologies (HK) Limited entered into an agreement to acquire Heyu Biological Technology Corporation (OTCPK:HYBT.D) in a reverse merger transaction for HKD 4.4 billion.	23-08-22	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Insider Buy: Heyu Biological Technology	23-05-31	MT
Heyu Biological Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	23-03-22	CI
Heyu Biological Technology Corporation Appoints Zengqiang Lin as an Independent Director of the Company	23-02-22	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23-02-13	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	23-02-10	CI
Heyu Biological Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	22-03-31	CI
Heyu Biological Technology Corporation Appoints Bo Lyu as Chief Financial Officer	21-11-30	CI

Chart Hongchang International Co., Ltd

Duration

Period

More charts

Company Profile

Hongchang International Co Ltd, formerly Heyu Biological Technology Corp, is a holding company mainly engaged in research and development and manufacture a medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the Chamber). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HONGCHANG INTERNATIONAL CO., LTD	-42.63%	156M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B